Randomized phase II trial of IGRT with or without HDR boost in intermediate-risk prostate cancer

被引：1
|
作者：
Vigneault, E. [1 ]
Morton, G. [2 ]
Perulekar, W. [3 ]
Niazi, T. [4 ]
Springer, G. [5 ]
Barkati, M. [6 ]
Chung, P. [7 ]
Koll, W. [8 ]
Kamran, A. [9 ]
Montreal, M. [3 ]
Ding, K. [3 ]
Loblaw, A. [2 ]
机构：
[1] CHU Quebec, Hotel Dieu Quebec, Radiat Oncol & Res Ctr, Quebec City, PQ, Canada
[2] Odette Canc Ctr, Radiat Oncol, Toronto, ON, Canada
[3] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[4] Mc Gill Jewish Gen Hosp, Dept Radiat Oncol, Montreal, PQ, Canada
[5] Windsor Reg Hosp, Radiat Oncol, Windsor, ON, Canada
[6] CHUM Hop Notre Dame, Radiat Oncol, Montreal, PQ, Canada
[7] Univ Hlth Network, Princess Margaret Canc Ctr, Radiat Oncol, Toronto, ON, Canada
[8] Lakeridge Hosp, Radiat Oncol, Oshawa, ON, Canada
[9] Dr H Bliss Murphy Canc Ctr, Radiat Oncol, St John, NF, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2017年 / 123卷
关键词：
D O I：
10.1016/S0167-8140(17)32136-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-1774
引用
收藏
页码：S975 / S976
页数：2
相关论文
共 50 条
  • [1] Toxicity and Quality of Life Outcomes from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer
    Hasan, Y.
    Loblaw, D. A.
    Chung, H. R.
    McGuffin, M.
    Tseng, C. L.
    Mendez, L. C.
    Ravi, A.
    Zhang, L.
    Mamedov, A.
    Morton, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S133 - S133
  • [2] TOXICITY AND QUALITY OF LIFE RESULTS FROM A RANDOMIZED PHASE II TRIAL OF HDR MONOTHERAPY FOR LOW AND INTERMEDIATE-RISK PROSTATE CANCER
    Hasan, Yaser
    Loblaw, Andrew
    Chung, Hans
    McGuffin, Merrylee
    Tseng, Chia-Lin
    Mendez, Lucas
    Ravi, Ananth
    Zhang, Liying
    Mamedov, Alexandre
    Morton, Gerard
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S36 - S36
  • [3] A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates
    Hahn, Andrew W.
    Manyam, Ganiraju C.
    Chapin, Brian F.
    Zhang, Miao
    Yu, Yao
    Pettaway, Curtis A.
    Chery, Lisly
    Pisters, Louis L.
    Ward, John F.
    Gregg, Justin R.
    Papadopoulos, John
    Kamat, Ashish M.
    Lozano, Marisa
    Hoang, Anh
    Broom, Bradley
    Wang, Xuemei
    Huff, Chad D.
    Logothetis, Christopher J.
    Troncoso, Patricia
    Pilie, Patrick G.
    Davis, John W.
    BJU INTERNATIONAL, 2024, 134 (03) : 449 - 458
  • [4] Survial Endpoints Comparing HDR BT Boost To EBRT Boost For High/Intermediate-Risk Prostate Cancer.
    Rodriguez Villalba, S.
    Richart Sancho, J.
    Perez-Calatayud, J.
    Lago Martin, J. D.
    Santos Ortega, M.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S1253 - S1254
  • [5] Phase I/II trial of HDR-brachytherapy boosted comprehensive IMRT for intermediate-risk adenocarcinoma of the prostate
    Hagan, M.
    Todor, D.
    Dogan, N.
    Wu, Y.
    Anscher, M.
    Arthur, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S363 - S363
  • [6] Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer.
    D'alimonte, Laura
    Helou, Joelle Antoine
    Morton, Gerard
    Chung, Hans T.
    McGuffin, Merrylee
    Ravi, Ananth
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial
    Nabid, Abdenour
    Carrier, Nathalie
    Vigneault, Eric
    Van Nguyen, Thu
    Vavassis, Peter
    Brassrard, Marc-Andre
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Wilke, Derek
    Souhami, Luis
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : 732 - 740
  • [8] LDR-HDR boost in patients with intermediate-risk prostate cancer. A single Institution experience
    Rodriguez Villalba, S.
    Monasor Denia, P.
    Richart Sancho, J.
    Acosta Rojas, A.
    Perez-Calatayud, M. J.
    Perez-Calatayud, J.
    Santos Ortega, M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S200 - S201
  • [9] Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial
    Belliveau, C.
    Barkati, M.
    Delouya, G.
    Taussky, D.
    Beauchemin, M. C.
    Lambert, C.
    Beaulieu, L.
    Beliveau-Nadeau, D.
    Nicolas, B.
    Carrier, J. F.
    Vigneault, E.
    Menard, C.
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [10] Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial
    C. Belliveau
    M. Barkati
    G. Delouya
    D. Taussky
    M. C. Beauchemin
    C. Lambert
    L. Beaulieu
    D. Beliveau-Nadeau
    B. Nicolas
    J. F. Carrier
    E. Vigneault
    C. Ménard
    Radiation Oncology, 17
12345